Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice

Simon Bélanger,[1] Megan M. Tu,[2] Mir Munir Ahmed Rahim,[2] Ahmad B. Mahmoud,[2] Rajen Patel,[2] Lee-Hwa Tai,[1] Angela D. Troke,[2] Brian T. Wilhelm,[3] Josette-Renée Landry,[3] Qinzhang Zhu,[4] Kenneth S. Tung,[5] David H. Raulet,[6] and Andrew P. Makrigiannis[2]

[1]Department of Microbiology and Immunology, McGill University, Montreal, QC; [2]Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON; [3]Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC; [4]Transgenic Core Facility, Clinical Research Institute of Montreal, Montreal, QC; [5]Department of Pathology, University of Virginia, Charlottesville, VA; and [6]Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA

Ly49-mediated recognition of MHC-I molecules on host cells is considered vital for natural killer (NK)–cell regulation and education; however, gene-deficient animal models are lacking because of the difficulty in deleting this large multigene family. Here, we describe NK gene complex knockdown (NKC^KD) mice that lack expression of Ly49 and related MHC-I receptors on most NK cells. NKC^KD NK cells exhibit defective killing of MHC-I–deficient, but otherwise normal, target cells, resulting in defective rejection by NKC^KD mice of transplants from various types of MHC-I–deficient mice. Self–MHC-I immunosurveillance by NK cells in NKC^KD mice can be rescued by self–MHC-I–specific Ly49 transgenes. Although NKC^KD mice display defective recognition of MHC-I–deficient tumor cells, resulting in decreased in vivo tumor cell clearance, NKG2D- or antibody-dependent cell-mediated cytotoxicity–induced tumor cell cytotoxicity and cytokine production induced by activation receptors was efficient in Ly49-deficient NK cells, suggesting MHC-I education of NK cells is a single facet regulating their total potential. These results provide direct genetic evidence that Ly49 expression is necessary for NK-cell education to self–MHC-I molecules and that the absence of these receptors leads to loss of MHC-I–dependent "missing-self" immunosurveillance by NK cells. (*Blood*. 2012; 120(3):592-602)

Introduction

Natural killer (NK) cells are a unique and integral part of the innate immune system. Persons without NK cells or lacking normal NK-cell activity experience persistent and life-threatening infections of normally innocuous viruses.[1,2] NK cells are able to distinguish normal cells from unhealthy cells by monitoring surface expression of a variety of molecules. The most well-characterized self-recognition system involves surveillance of host class I MHC (MHC-I) molecules, a process initially described by the missing-self hypothesis.[3] This hypothesis states that target cells lacking normal expression of self–MHC-I molecules because of viral infection or transformation are specifically recognized and lysed by NK cells.

Several surface receptors are known to activate or inhibit the function of NK cells. Numerous NK-cell receptors such as the NKG2D, CD94/NKG2, NKR-P1, and Ly49 families of C-type lectin-like transmembrane proteins are encoded in a region on mouse chromosome 6 termed the NK gene complex (NKC). The most well-characterized MHC-I–specific receptors on mouse NK cells are the Ly49, which represent the mouse functional equivalents of the human killer-cell Ig-like receptor family. The *Klra* (Ly49) gene family is highly polymorphic, with significant variation in gene content between mouse strains.[4] The *Klra* haplotype of 129-strain mice contains 19 genes that encode 3 activating and 9 inhibitory receptors; the remaining genes are pseudogenes.[5]

Ly49 receptors are divided into 2 main groups: activating and inhibitory receptors. Activating Ly49 receptors have been implicated in direct recognition of virally encoded MHC-I–like molecules on infected target cells.[6] Most inhibitory Ly49 receptors recognize specific MHC-I molecules, resulting in some Ly49 that can bind "self" MHC-I and some that cannot. Rare self–MHC-I receptor-negative NK cells display hyporesponsive cytotoxic and cytokine potential in response to activation signals.[7,8] Conversely, the greater the number of self–MHC-I receptors expressed by NK cells, the greater the response after activation.[9] Therefore, in addition to target cell differentiation by mature NK cells, Ly49 molecules are hypothesized to also be required during NK-cell development, specifically for education to self-MHC expression. We have generated a mutant mouse strain in which the expression of Ly49 molecules is absent on most NK cells. In this study, we assess the development and the function of NK cells in Ly49-deficient mice and show that Ly49 receptors are directly responsible for NK-cell education and immunosurveillance to self–MHC-I in vivo.

Methods

Mice

C57BL/6 (B6), 129S1, and $B2m^{-/-}$ on the B6 background mice were purchased from The Jackson Laboratory. $H2K^{b-/-}$, $H2D^{b-/-}$, and $H2K^{b-/-}D^{b-/-}$ mice on

---

a B6 background were purchased from Taconic Farms. The generation of Ly49A[tg] (B6 background), Ly49G[tg] (B6 background), Ly49I[tg] (FVB background), Rae-1ε[tg] (B6 background), and B6.Ly49[129] mice was previously described.[10-14] Ly49I[tg] mice were kindly provided by Dr Michael Bennett (University of Texas, Dallas). NKC[KD] mice were generated by targeting *Klra15* in *Klra17[lox/wt]* (Ly49q[lox/wt]) R1 embryonic stem (ES) cells. Neomycin-resistant ES cells were electroporated with CMV-Cre plasmid and were selected by PCR with the use of the following primers: 5′-GGCTTGAAGACTCAGGGTTTTGCTC and 5′-TCTTGACCCTTGATTGTCCTCAGGC. Homozygous *Klra15*-targeted mice were determined with an additional PCR for the absence of *Klra17[wt]* with the use of the following primers: 5′-CCTAAAAGTAATTGCT-GTGACTATT and 3′-CTTTCTAACTAGCTAACAACAG. B6. NKC[KD] mice were produced by backcrossing NKC[KD] mice to the B6 background for 10 generations and selecting for the 129-specific *Klra22* (Ly49v) gene as described,[14] followed by single nucleotide polymorphism analysis with the use of an Illumina Beadstation 500G mouse medium density linkage panel (The Center for Applied Genomics–Sick Kids Hospital). The genome of B6.NKC[KD] mice is of B6 origin except for a region containing the NKC on chromosome 6 spanning nucleotides 127, 954, 449-138, 203, 431 deduced from single nucleotide polymorphism markers rs3681620 and rs13479071, respectively. Ly49 transgenes were introduced by breeding to B6.NKC[KD] mice. Ly49-transgene genotyping was performed as described.[10-12] Ly49 transgene–positive, NKC[KD] heterozygous mice were then bred to homozygosity for the NKC[KD] chromosome. Third-generation mice homozygous for the Ly49 transgene were used for experiments. Ly49 expression was tested with Ly49 mAb to verify Ly49 transgenes and NKC[KD] backgrounds. All breeding and manipulations performed on animals were in accordance with university guidelines and approved by the University of Ottawa Animal Ethics Committee.

Cells

RMA-S cells were stably transfected with Rae-1β-pEF6 vector with the use of Lipofectamine 2000 (Invitrogen). The C1498 MHC-I–negative variant was produced by 3 rounds of ethylmethane-sulfonate[3] (Sigma-Aldrich) treatment and sorting $\beta_2 m^{lo}$ cells. In parallel, C1498 cells were treated with EMS but not sorted to generate C1498 MHC-I–positive cells. Adherent lymphokine-activated killer (LAK) cells were generated as previously described.[15]

Semiquantitative RT-PCR and genomic PCR

RNA was isolated from LAK cells with the use of TRIzol reagent (Invitrogen). cDNA was synthesized with the Superscript First-Strand cDNA synthesis kit (Invitrogen). Semiquantitative RT-PCR was performed on serial 5-fold dilutions of cDNA with the use of gene-specific primers.[5,16-18] Semiquantitative PCR to verify the presence of the concatemer was performed on genomic DNA with the use of the following primers as depicted in Figure 1D: 5′ forward out, 5′-CCAGTCCTAAATCTGATAGG; 5′ forward in, 5′-GCTGGCCGTTATCATGTTGA; 5′ reverse, 3′-ACAGTCTCCCTTGCCTGTAG; 3′ forward, 5′-GGTATGGTTTAAC-CCACTCA; 3′ reverse in, 3′-GGTGCCTCGAGTGGTTTCTA; and 3′ reverse out, 3′-TTCTGTAGCCAGCTTCTCTG.

Antibodies and flow cytometry

Anti-CD49b, anti-TCRβ, anti-CD16, anti–LFA-1, anti-CD44, anti-CD62L, anti-CD2, anti-CD11b, anti-CD122, anti-NKp46, anti-CD43, anti-CD27, anti-CD69, anti-Thy1.2, anti-NKG2D, anti-CD94, anti-Ly49A/D, anti-Ly49C/I/F/H, anti-CD107a, anti–granzyme B, anti-KLRG1, anti–IFN-γ, rIgG$_1$, and rIgG$_{2b}$ were purchased from eBioscience. Anti-NKG2A/C/E, anti-Ly49D, anti-Ly49G, and anti-β$_2$m were purchased from BD Biosciences. Anti-B220 was purchased from Miltenyi Biotec. Anti–granzyme A was purchased from Santa Cruz Biotechnology. Anti-CRACC was a gift from Dr André Veillette (Clinical Research Institute of Montreal). Fc receptors were blocked with rat serum (Sigma-Aldrich), and dead cells were excluded with propidium iodide (BD Biosciences). Flow cytometry was performed on a CyAN-ADP with the use of Summit Version 4.3 software (Beckman Coulter). Data were analyzed with Kaluza Version 1.2 software.

In vitro NK-cell assays

Cytotoxicity experiments were performed as previously described.[15] ConA blast target cells were prepared by culturing 2.5×10^6 cells/mL of splenocytes for 2 days in cRPMI containing 5 μg/mL ConA (Sigma-Aldrich). To measure production of IFN-γ, 1×10^6 splenocytes isolated from poly(I:C)–treated mice (150 μg; 18 hours earlier) were incubated for 5 hours with target cells (1:1 ratio) or in plates coated with 1 μg/mL anti-NKp46 antibody. GolgiPlug (BD Biosciences) was added to the wells after 1 hour. Cells were stained for CD49b, TCRβ, and for Ly49I, Ly49O, Ly49V, and NKG2A; fixed; permeabilized with the Cytofix/Cytoperm kit (BD Biosciences); and then stained for IFN-γ or with an isotype-matched control mAb. For antibody-dependent cellular cytotoxicity (ADCC), after ^{51}Cr-labeling, target cells were incubated in the presence of 10 μg/mL anti-Thy1.2 mAb for 30 minutes and then washed before use. For blocking NKG2D-ligand interactions, anti-NKG2D mAb was added directly to wells containing effector cells for a final concentration of 10 μg/mL and incubated 20 minutes after which time targets were added.

In vivo NK-cell assays

The splenocyte rejection assay was performed as previously described.[14] NK cells were depleted by intraperitoneal injection of 40 μL of anti–asialo-GM1 (Wako Chemicals) 2 days before poly(I:C) injection. MHC-I–positive and MHC-I–negative tumor cells were differentially labeled with 0.5μM and 5μM of CFSE (Invitrogen). A mixture of 1×10^6 cells of each type was injected intraperitoneally into B6-background recipient mice. After 6 hours (C1498 and C1498 MHC-I) or 18 hours (RMA and RMA-S), peritoneal cells were harvested and analyzed for the presence of CFSE-labeled tumor cells by flow cytometry.

Southern blot analyses

Restriction fragment-length polymorphism analysis was performed on DNA isolated from the thymus and digested with *Eco*RI, *Kpn*I, or *Bam*HI. Blots were probed with a mixture of *Klra7* (Ly49g) and *Klra5* (Ly49e) cDNAs. The presence of the concatemer was discovered by probing with a fragment of the *Klra15*-targeting construct.

Genome analysis

Oligonucleotides for tiling microarrays were designed with a custom Perl script on the Repeatmasked (Smit AFA, Hubley R, Green P. RepeatMasker Open-3.0. 1996-2010; http://www.repeatmasker.org) 129S6 genomic sequence spanning the *Klra* cluster and flanking genes (693 835 bp). In addition, a 5-Mbp Repeatmasked region, centered on the B6 *Klra* cluster (National Center for Biotechnology Information 37:chr6:127300000-132300000), was also used to design tiling array probes. All 60-bp probes were tiled at approximately every 15 bp, and the custom arrays were subsequently generated by NimbleGen. Hybridizations were performed by the functional genomic platform at the Institute for Research in Immunology and Cancer. Genomic DNA from wild-type (WT) and NKC[KD] mice were labeled with cyanine 5 (Cy5)– and Cy3-labeled 9mers (Trilink Technologies) with the use of 3′-5′ exo-Klenow fragment (New England Biolabs), and a dye swap was performed. Two-color hybridizations were performed with 6 μg of Cy5-labeled and 6 μg of Cy3-labeled gDNA with the use of the NimbleGen hybridization kit as recommended by the manufacturer. Arrays were scanned at 5-μm resolution with the use of a GenePix4000B scanner (Molecular Devices). The data discussed in this article have been deposited in Gene Expression Omnibus from the National Center for Biotechnology Information and are accessible through GEO Series accession no. GSE38372 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE38372). Data from scanned images were extracted and analyzed with NimbleScan 2.5 extraction software (NimbleGen Systems).

Statistical analysis

Statistical significance was determined by a 2-tailed unpaired Student *t* test with a cutoff *P* value of .05. Data are presented as ± SD.

Figure 1. The *Klra* gene cluster of *Klra15*-targeted (mutant) mice contains a concatemer insertion of the *Klra15*-targeting construct. (A) A schematic representation of the natural killer gene complex (NKC) and the targeting-construct produced for the *Klra15* gene. (B) Southern blot analysis of wild-type (WT) and mutant thymus DNA digested with *Eco*RI, *Kpn*I, or *Bam*HI and probed with the *Klra15*-targeting construct depicted in panel A. (C) Array comparative genomic hybridization profile of the *Klra* cluster in mutant mice with a blow-up of the *Klra15* gene (below). The x-axis represents the genomic region tiled on the microarrays, and the y-axis Shows differences in copy number between WT and mutant genomic DNA (log$_2$ ratio [MT/WT]). Positive values indicate regions showing copy number increases in the NKC knockdown (NKC^{KD}) genome. (D) PCR analysis of the *Klra15*-targeting construct copy number in mutant genomic DNA. Data are representative of ≥ 3 similar experiments, except for array comparative genomic hybridization analysis, which was performed twice. These experiments were performed with mice on the 129S1 background.

Results

Generation of mice containing a concatemer upstream of the *Klra* gene cluster

In an effort to delete the *Klra* gene cluster, the *Klra15* (Ly49o) promoter region was targeted with a floxed PGK-Neo selection cassette in ES cells carrying a *Klra17^lox* allele previously used to make Ly49Q-deficient mice (Figure 1A).[19] After generating mice from double-targeted, CMV-Cre electroporated ES cells, it was discovered that the long-range deletion was unsuccessful because

of nonhomologous recombination of the *Klra15*-targeting construct, resulting in a total gain of DNA sequence. When a portion of the *Klra15*-targeting construct was used to probe digested genomic DNA from WT and mutant mice, a 10- to 12-kb DNA fragment hybridized very strongly only in mutant mouse DNA (Figure 1B). Array comparative genomic hybridization analyses confirmed that the gained sequence originated from the *Klra15*-targeting construct (Figure 1C). These data suggest that the targeting construct integrated as a concatemer. The location of the concatemer was verified to be at the intended recombination site of the *Klra15* promoter region by semiquantitative PCR analysis of genomic

Figure 2. Klra15-targeted mice show a drastic reduction in telomeric NKC gene expression. (A) NK cells (DX5+TCRβ−) from the spleens of WT or mutant mice were analyzed for Ly49 expression with mAbs 4E5 (which binds Ly49O/V/R in mice with a 129-strain *Klra* gene cluster), 12A8 (Ly49R), 4D11 (Ly49G/T), and 14B11 (Ly49I) individually or as a cocktail (Total Ly49). The percentage of NK cells positively stained is indicated. (B) The mean ± SD percentage of different splenic NK-cell subsets present in WT, mutant, and heterozygous littermates (n = 5) is shown graphically. (C) Semiquantitative RT-PCR of cDNA for the indicated genes was performed on total RNA obtained from lymphokine-activated killer cells prepared from 2 individual WT or mutant mouse spleens. (D) The expression of NKG2/CD94 family of receptors on splenic NK cells from WT or mutant littermates. Data are representative of ≥ 3 similar experiments. These experiments were performed with mice on the 129S1 background.

DNA with the use of primers either within or outside the concatemerized targeting construct (Figure 1D).

Ly49, NKG2, CD94, and KLRI expression is silenced in NKC^KD mice

Initial analysis of Ly49O surface expression showed significant loss of positively staining NK cells from homozygous mutant mice relative to WT littermate controls (Figure 2A). Unexpectedly, additional staining of NK cells from *Klra15*-targeted mice with mAb specific for Ly49V, Ly49R, Ly49G, Ly49T, and Ly49I, individually or as a cocktail, showed that these subsets were also decreased by 70%-80% (Figure 2A-B). These results were surprising, because no other *Klra* genes were intentionally targeted during ES cell manipulation. Interestingly, heterozygous mice have near normal Ly49+ NK cells subsets, although a completely stochastic model of Ly49 acquisition would predict intermediate numbers (Figure 2B). *Klra* down-regulation was detectable at the level of mRNA (Figure 2C). Thus, the mechanism of Ly49 down-regulation may involve multilocus transcriptional silencing.

The residual Ly49+ NK cells from *Klra15*-targeted mice lost on average ∼ 50% of Ly49 receptor coexpression (supplemental Figure 1A, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Therefore, NK cells from mutant mice are mostly Ly49− and the remaining Ly49+ cells have a greatly decreased probability of expressing multiple Ly49. Restriction fragment-length polymorphism analysis of WT and mutant mouse genomic DNA with *Klra* cDNAs as probes resulted in highly similar patterns (supplemental Figure 1B), suggesting that Ly49 down-regulation is not because of gene deletion. The observed gene down-regulation was not limited to *Klra* genes;

neighboring genes in the NKC were also affected, albeit to a degree dependent on the proximity to the *Klra* locus (Figure 2C-D). Because of the overall NK-cell receptor expression phenotype of these mice, they are referred to as NKC-knockdown (NKC^KD) mice hereafter.

In summary, the attempted gene targeting of *Klra15* resulted in an insertion of the *Klra15*-targeting construct as a concatemer upstream of the *Klra* gene cluster. This insertion leads to regional transcriptional silencing and subsequent loss of most Ly49 receptor expression on NKC^KD NK cells, including additional down-regulation of neighboring genes encoding the CD94/NKG2 and KLRI receptor families.

NKC^KD NK cells display normal development and maturation markers

Next, we determined whether NKC^KD NK-cell development, localization, or differentiation marker expression was affected. NK-cell numbers and percentages in the spleen, lungs, liver, and blood are similar in WT and NKC^KD mice (supplemental Figure 2A). Twelve markers expressed by NK cells were found to be normally expressed (supplemental Figure 2B). In addition, the NKC-resident *Klrb1b, Clec2d,* and *Clec2i* genes were unaffected (supplemental Figure 3A). NKC^KD NK cells cultured in IL-2 for 3 days contained normal levels of granzymes A and B (supplemental Figure 3B). Similarly, up-regulation of CD69 was normal, but the number of NKC^KD NK cells expressing the KLRG1 activation marker was reduced (supplemental Figure 3B-C), similar to B6 strain Ly49C, Ly49I, NKG2A-negative NK cells, and NK cells from *B2m*−/− mice.[7,20] In summary, the deficiency of NKC^KD mice

Figure 3. Natural killer gene complex knockdown (NKC^KD) NK cells exhibit defective in vitro killing of MHC-I–deficient ConA blasts, and NKC^KD mice exhibit reduced rejection of MHC-I–deficient splenocytes in vivo. The ability of lymphokine-activated killer (LAK) cells from WT and NKC^KD to kill splenic ConA blast target cells from (A) B6 (WT), (B) *B2m^−/−*, (C) *H2K^b−/− H2D^b−/−*, (D) *H2K^b−/−*, (E) *H2D^b−/−*, and (F) Rae-1ε transgenic (Rae-1ε^tg) mice was tested by ⁵¹Cr-release assay. Data are represented as the mean ± SD percentage of chromium release from triplicate wells. Data are representative of 3 similar experiments. Cytotoxicity experiments were performed with mice on the B6 background. (G) The ability of WT and NKC^KD mice to reject CFSE-labeled splenocytes from *B2m^−/−*, *H2K^b−/− H2D^b−/−*, *H2K^b−/−*, and *H2D^b−/−* mice was tested by flow cytometry of recipient splenocytes 16 hours after injection. Each symbol represents the data from an individual mouse, and the small horizontal lines indicate the mean. Some mice of each strain were pretreated with anti–asialo-GM1 Ab to deplete NK cells before injection of CFSE-labeled cells. Data are pooled from 3 to 5 independent experiments. Groups differed significantly as shown (***P < .001; NS, not significant). (H) Time-course rejection assay of *B2m^−/−* splenocytes by WT and NKC^KD mice. Data are displayed as the mean ± SEM rejection of 6 individual mice. Splenocyte rejection experiments were performed with 129S1 background mice.

appears to be restricted to only NKC-encoded MHC-I–specific receptor expression on mature NK cells.

NKC^KD NK cells exhibit defective natural killing of MHC-I–deficient hematopoietic cells

NKC^KD mice provide a genetic model to directly test the "missing-self" hypothesis. First, in vitro cytotoxicity assays were used with ConA-stimulated lymphoblasts from MHC-I–sufficient or MHC-I–deficient mice as target cells. Effector LAK cells were produced from B6 background WT (B6.Ly49^129) and NKC^KD mice as initial experiments with 129-background LAK cells yielded low in vitro killing, as previously observed for this strain.[14] Both WT and NKC^KD LAK cells were unable to kill WT ConA blasts (Figure 3A). In contrast, *B2m^−/−* ConA blasts were lysed efficiently by WT LAK cells (Figure 3B). However, NKC^KD LAK killing of *B2m^−/−* blasts was considerably lower (Figure 3B). Similarly, the killing of *H2K^b−/− H2D^b−/−* ConA blasts was high for WT LAK cells and ~ 50% lower for NKC^KD LAK cells (Figure 3C). *H2K^b−/−* ConA blasts were also efficiently killed by WT LAK cells, but poorly lysed by NKC^KD LAK cells (Figure 3D). In contrast, low killing of *H2D^b−/−* ConA blasts was exhibited by either WT or NKC^KD LAK cells (Figure 3E). To control for cytotoxic potential independent of MHC-I, ConA blasts were prepared from Rae-1ε–transgenic mice and used as target cells. These were equally and efficiently lysed by

both WT and NKC^KD LAK cells (Figure 3F) as well as freshly prepared NK cells (data not shown), showing that the decreased killing of MHC-I–deficient blasts by NKC^KD LAK cells is not because of lower overall killing ability.

To determine whether NKC^KD NK cells effectively monitor the expression of MHC-I in vivo, splenocyte rejection assays were conducted. Approximately 80% of *B2m^−/−* splenocytes are rejected by WT mice after 16 hours; however, NKC^KD mice displayed only half as much rejection (Figure 3G). The weak rejection displayed by NKC^KD mice is probably because of residual Ly49 expression, resulting in low numbers of MHC-I–educated NK cells. The rejection by NKC^KD mice of splenocytes specifically deficient in MHC-Ia molecules was also tested. Rejection of *H2K^b−/− H2D^b−/−* splenocytes by WT mice was ~ 20% lower than rejection of *B2m^−/−* splenocytes but still 3 times as much as that mediated by NKC^KD mice (Figure 3G). Rejection of both *B2m^−/−* and *H2K^b−/− H2D^b−/−* splenocytes was due to NK cells as shown by pretreatment of recipient mice with anti–asialo-GM1 antiserum (Figure 3G).

The ability of NKC^KD mice to destroy cells missing single MHC-Ia molecules was determined. The rejection of *H2K^b−/−* splenocytes by WT mice was less than that observed for *H2K^b−/− H2D^b−/−* splenocytes, but NKC^KD mice rejected *H2K^b−/−* splenocytes significantly less well than WT mice (Figure 3G). The rejection of *H2D^b−/−* splenocytes by both WT and NKC^KD mice was low (Figure 3G). To determine whether

Figure 4. Loss of MHC-I–immunosurveillance in NKC^{KD} mice is because of silencing of Ly49 that bind to self–MHC-I. Three different Ly49-transgenes were introduced into NKC^{KD} mice by breeding. (A-C) Flow cytometric analysis of Ly49 expression in Ly49^{tg}-NKC^{KD} NK cells. Ly49 staining of NK cells is shown for (A) NKC^{KD}-Ly49A^{tg}, (B) NKC^{KD}-Ly49G^{tg}, and (C) NKC^{KD}-Ly49I^{tg} mice as a black histogram. The gray histogram shows control staining of splenic NK cells from NKC^{KD}mice. (D-F) Specific rejection of $B2m^{-/-}$ splenocytes by (D) Ly49A^{tg}-NKC^{KD} mice, (E) Ly49G^{tg}-NKC^{KD} mice, (F) Ly49I^{tg}-NKC^{KD} mice in comparison to WT or NKC^{KD} mice. Each symbol represents the data from a single mouse. Data are pooled from 3 to 5 independent experiments. Groups differed significantly as shown (*$P < .05$; ***$P < .001$; NS indicates not significant). (G) LAK prepared from WT, NKC^{KD}, and NKC^{KD}-Ly49i^{tg} mice were used as effector cells in a ^{51}Cr-release assay against $B2m^{-/-}$ ConA blasts. These experiments were performed with mice on the B6 background.

the rejection of MHC-I–deficient cells was simply delayed, a time-course experiment was performed. As late as 40 hours after injection MHC-I–deficient cells are still present in NKC^{KD} mice even though there is close to 100% rejection in WT mice (Figure 3H). In summary, these data show that NKC^{KD} NK cells display specific defective in vitro and in vivo killing of MHC-I–deficient cells.

A self-specific Ly49 transgene restores MHC-I immunosurveillance in NKC^{KD} mice

To determine the direct contribution of Ly49 receptors to the deficient missing-self responses of NKC^{KD} mice, 3 different Ly49 transgenes were individually introduced onto the NKC^{KD} background via backcrossing. Ly49a, Ly49g, and Ly49i transgenes were expressed on most NK cells from NKC^{KD} mice (Figure 4A-C). Ly49a and Ly49g transgenes did not rescue the ability of NKC^{KD} mice to reject MHC-I–deficient cells (Figure 4D-E), in agreement with the known lack of binding of Ly49A and Ly49G to either K^b or D^b. However, transgenic expression of Ly49I, which binds to both K^b and D^b,[11,21] was able to restore most missing self-responses (Figure 4F). Furthermore, Ly49I expression on NK cells from NKC^{KD} mice restored in vitro cytotoxicity toward $B2m^{-/-}$ ConA blast target cells to normal levels (Figure 4G). Thus, Ly49 silencing is responsible for most deficient missing self-responses in NKC^{KD} mice. These data further support the hypothesis that Ly49 expression by NK cells for self-MHC-I during development results in the acquisition of cytotoxic potential to cells lacking self–MHC-I molecules.

Loss of tumor cell MHC-I surveillance in NKC^{KD} mice

The ability of NKC^{KD} NK cells to kill tumor cells was determined. It was observed that WT and NKC^{KD} LAK killing of MHC-I–sufficient RMA tumor cells was low (Figure 5A), showing that the diminished expression of MHC-I–specific receptors by NKC^{KD} NK cells does not result in a loss of inhibition. In contrast, the killing of the MHC-I–deficient variant RMA-S was higher; however, NKC^{KD} LAK cells killed RMA-S only half as well as WT LAK cells (Figure 5B), suggesting that the ability to respond to MHC-I–deficient cells requires MHC-I receptor expression during NK-cell development. ADCC of both RMA and RMA-S was equal between WT and NKC^{KD} LAK cells (Figure 5A-B), again showing that the intrinsic MHC-independent killing potential of NKC^{KD} NK cells is intact.

Similar to in vitro cytotoxicity results, NKC^{KD} mice displayed a significant reduction in the ability to reject RMA-S in vivo compared with WT mice (Figure 5C). Because RMA and RMA-S have been cultured separately for almost 30 years, it is possible that they have differentially acquired additional mutations, possibly contributing to NK-cell susceptibility. We produced an MHC-negative variant of the C1498 lymphoma by EMS treatment, followed by multiple rounds of cell sorting (Figure 5D). Similar to RMA-S, C1498–MHC-negative tumor cells were rejected only half as well by NKC^{KD} mice compared with WT controls (Figure 5E), emphasizing that Ly49 expression by NK cells is necessary for MHC-I immunosurveillance against cancer.

Figure 5. NKC[KD] NK cells exhibit reduced cytotoxicity toward MHC-I–deficient tumor cells in vitro and in vivo. (A-B) The ability of WT versus NKC[KD] lymphokine-activated killer (LAK) cells to kill tumor target cells was tested by ^{51}Cr-release assay. LAK cells generated from WT and NKC[KD] mice were used as effectors cells against untreated (A) RMA, (B) RMA-S target cells, or targets precoated with anti-Thy1.2 mAb to test antibody-dependent cellular cytotoxicity (ADCC) function. The data are displayed as the mean ± SD percentage of chromium release from triplicate wells. (C) In vivo rejection of RMA-S relative to RMA cells was assessed. The mean rejection is indicated by a horizontal line. Each symbol represents the data from a single mouse. (D) Production of a MHC-I–negative C1498 subline. Flow cytometry for β₂m (dark histogram) is shown for the indicated C1498 lines. The gray histogram indicates isotype control mAb staining. The percentage of cells positively staining for β₂m is indicated. (E) In vivo rejection of C1498-MHC-I–negative cells versus C1498-MHC-I–positive tumor cells. Note that both cell lines received EMS treatment. Data are representative of ≥ 3 similar experiments. Groups differed significantly as shown (**$P < .01$; ***$P < .001$). These experiments were performed with mice on the B6 background.

Defective killing of MHC-I–deficient tumor cells by NKC[KD] NK cells is restored by activation through NKG2D

To determine the effect of activating ligands expressed by MHC-I–negative tumors we tested the ability of NKC[KD] NK cells to kill the prototypical mouse NK tumor target cell YAC-1, which are MHC-low and express high levels of NKG2D ligands.[22,23] In contrast to RMA-S results, the killing of YAC-1 was found to be almost equally high by both WT and NKC[KD] LAK cells (Figure 6A), most probably because of the near normal expression of NKG2D (Figure 2D). We hypothesized that in the absence of overriding NKG2D activation signals YAC-1 should be differentially killed by WT versus NKC[KD] LAK cells. WT LAK killing decreased marginally in the presence of anti-NKG2D mAb, but NKC[KD] LAK killing was dramatically reduced to levels similar to NKC[KD] LAK killing of RMA-S (Figure 6A). To further test this hypothesis, RMA-S was stably transfected with Rae-1β. Similar to YAC-1, both WT and NKC[KD] NK cells exhibited high killing of RMA-S-Rae-1β target cells, with NKC[KD] killing being only slightly less than WT killing (Figure 6B). In addition, anti-NKG2D blocking of WT LAK decreased killing of RMA-S-Rae-1β only slightly, but killing by NKC[KD] LAK cells was considerably lower (Figure 6B). These results suggest that, although missing self-immunosurveillance against tumor cells is deficient in NKC[KD] mice, this deficiency can be masked by strong activating signals such as through NKG2D or CD16/CD32 (Figure 5B).

To determine whether these findings were unique to NK cells from NKC[KD] mice or to MHC-I–uneducated NK cells in general, YAC-1 killing by LAK from $B2m^{-/-}$ mice in the presence or absence of anti-NKG2D mAb was tested. Similar to NKC[KD] LAK cells, $B2m^{-/-}$ LAK killing of YAC-1 was slightly less than WT, but, in the presence of anti-NKG2D mAb, only $B2m^{-/-}$ LAK killing was considerably decreased, showing deficient missing self-responses (Figure 6C). A similar pattern was observed when using RMA-S-Rae-1β tumor cells as targets; high killing by both WT and $B2m^{-/-}$ LAK cells, but significantly decreased killing by blocking NKG2D only with $B2m^{-/-}$ LAK cells (Figure 6D).

It is possible that hyporesponsiveness is being masked by IL-2 activation of LAK cells. However, the in vivo rejection of RMA-S-Rae-1β cells by both WT and NKC[KD] mice was considerably increased (Figure 6E) compared with rejection of parental RMA-S cells (Figure 5C) and mirrored in vitro cytotoxicity assay results (Figure 6B). Similarly, the rejection of $B2m^{-/-}$Rae-1[tg] splenocytes was efficient in both WT and NKC[KD] mice, but slightly less for NKC[KD] mice (Figure 6F), suggesting a small effect by the self-education defect in NKC[KD] mice. Finally, the killing of YAC-1 by fresh ex-vivo NK cells from WT, NKC[KD], and $B2m^{-/-}$ mice (Figure 6G) was tested. YAC-1 cells were killed by fresh NKC[KD] NK cells as efficiently as WT NK cells, arguing against hyporesponsiveness being masked by IL-2 activation in the LAK cytotoxicity experiments. However, $B2m^{-/-}$ NK cells showed a moderate defect in YAC-1 killing compared with WT NK cells (Figure 6G). In summary, these data suggest that defective self–MHC-I education, whether through absence of receptors (NKC[KD] mice) or absence of ligands ($B2m^{-/-}$ mice), still allows NK cells to display cytotoxicity toward tumor cells bearing strong activating ligands.

NKC[KD] NK cells display normal cytokine and degranulation responses

In contrast to killing of MHC-I–deficient target cells, de novo intracellular IFN-γ protein synthesis after stimulation with RMA-S or YAC-1 tumor cells, anti-NKp46 mAb, phorbol 12-myristate 13-acetate/ionomycin, or after murine CMV (MCMV) infection was normal in NKC[KD] NK cells compared with WT NK cells (Figure 7A-B). When the ability of specific NK subsets is analyzed,

Figure 6. Activation via NKG2D overcomes deficient missing-self responses by natural killer gene complex knockdown (NKC^KD) and _B2m^−/−_ NK cells to tumor cells. (A-B) The cytotoxic potential of WT versus NKC^KD LAK cells against (A) YAC-1 and (B) RMA-S-Rae-1β target cells was assessed by ^51Cr-release assay in the presence or absence of blocking anti-NKG2D. (C-D) Similarly, cytotoxicity of WT versus _B2m^−/−_ LAK cells was assessed against (C) YAC-1 and (D) RMA-S-Rae-1β target cells in the presence or absence of blocking anti-NKG2D. The data are displayed as the mean ± SD percentage of chromium release from triplicate wells. (E-F) In vivo rejection of (E) RMA-S-Rae-1β relative to RMA cells or of (F) _B2m^−/−_Rae-1e^tg splenocytes relative to WT splenocytes was assessed. The mean rejection is indicated by a horizontal line. Each symbol represents the data from a single mouse. Data are representative of ≥ 3 similar experiments. Groups differed significantly as shown (***P < .001). (G) Splenocytes from the indicated mouse strains were used in cytotoxicity assays against ^51Cr-labeled YAC-1 cells at the indicated effector-to-target ratios. The data are displayed as the mean ± SD of chromium release from triplicate wells. These experiments were performed with mice on the B6 background.

either positive or negative for inhibitory self-MHC-I–specific receptors, more IFN-γ is produced by the Ly49/NKG2^+ subset than the Ly49/NKG2^− subset in WT NK cells (Figure 7C), in accordance with the licensing/education hypothesis, regardless of the type of stimulus. The corresponding Ly49/NKG2^+ subset had the same frequency of IFN-γ^+ NK cells in NKC^KD mice

Figure 7. NKC^KD NK cells display normal IFN-γ production and degranulation responses. (A) Splenocytes from WT or NKC^KD mice pretreated with poly(I:C) were incubated with the indicated tumor cells, on plates coated with anti-NKp46 mAb or with phorbol 12-myristate 13-acetate (PMA)/ionomycin. After 5 hours intracellular staining was performed to assess IFN-γ production by flow cytometry. (B) The frequency of IFN-γ^+ NK cells was assessed in the spleens of the indicated mouse strains after 36 hours of infection with Smith strain murine CMV (MCMV). (C) The same assay as in panel A was performed, but splenocytes were additionally stained with anti-Ly49 and NKG2A mAb. Data are shown as the percentage of IFN-γ^+ cells among Ly49/NKG2^+ and Ly49/NKG2^− subsets. (D) CD107a levels on the surface of NK cells were evaluated by flow cytometry after the indicated tumor or mAb stimulations. Mice were pretreated with poly(I:C) or with a PBS control. Data are representative of ≥ 3 similar experiments, except for degranulation assays which were performed twice. Three individual mice were used as a source of splenocytes for each experiment (n = 3). These experiments were performed with mice on the B6 background.

compared with WT mice (Figure 7C), although the Ly49/NKG2$^+$ subset is 5 times smaller in NKC^{KD} mice; thus, it cannot account for the normal levels of IFN-γ among bulk NK cells. Surprisingly, the Ly49/NKG2$^-$ subset of NKC^{KD} NK cells produced significantly more IFN-γ than the corresponding subset in WT NK cells (Figure 7C).

Similar to IFN-γ induction, the degranulation potential of NKC^{KD} NK cells was normal in response to tumor target cell coincubation or plate-bound anti-NKp46 mAb stimulation, as detected by CD107a surface expression (Figure 7D). The reason RMA-S did not elicit lower CD107a on NKC^{KD} NK cells is not clear, although other studies have found discrepancies between CD107a levels and actual lysis of target cells.[24] Thus, bulk NKC^{KD} NK cells display normal IFN-γ and degranulation responses despite most of these cells being Ly49$^-$, suggesting Ly49 expression is not strictly required for these functions.

Discussion

We show that NK-dependent in vitro killing and in vivo rejection of MHC-I–deficient cells is significantly lower in NKC^{KD} mice and that this deficiency can be rescued by a Ly49 transgene. These results are consistent with the hypothesis that self–MHC-I–specific inhibitory Ly49 expression during NK-cell development is necessary for NK cells to achieve responsiveness toward MHC-I–deficient cells. If the only function of Ly49 is inhibition in mature NK cells, then the loss of Ly49 should result in the increased killing of MHC-I$^+$ cells. However, the lack of RMA tumor cell and WT ConA blast killing by NKC^{KD} NK cells argues against this model. One explanation is that NKC^{KD} NK cells are simply "abnormal" and lack cytotoxic ability, but their high and normal killing of YAC-1 and Rae-1ϵ^{tg} ConA blasts, as well as ADCC-mediated killing, shows that NKC^{KD} NK cells have a normal cytotoxic potential. The data best fit a model whereby self–MHC-I–specific inhibitory Ly49 receptor expression is required during NK-cell development and education for the subsequent acquisition of cytotoxicity that can be specifically triggered by the loss of self–MHC-I on target cells. This new animal model provides direct genetic evidence of Ly49-mediated NK-cell education in addition to complementing and extending previous genetic reconstitution experiments with adoptively transferred bone marrow cells.[8]

The down-regulation of the whole Ly49 gene cluster after targeting of the most upstream/telomeric gene is reminiscent of the first granzyme- and globin-targeted mice, which unintentionally resulted in silencing of the other gene family members.[25] In these cases, the neomycin selection cassettes are thought to have contributed to the silencing effect. However, Southern blot analysis showed that NKC^{KD} mice contain no neomycin genes because of Cre-mediated deletion at the ES cell stage, in agreement with the inability of NKC^{KD} NK cells to survive in neomycin-containing culture medium (data not shown). The granzyme and globin gene families are hypothesized to be under the control of a locus control region (LCR) that governs expression temporally and with regard to tissue/cell type.[25] The silencing of the whole gene cluster is possibly a result of the concatemer insertion interrupting an LCR-mediated opening of the cluster. There is currently no evidence that the *Ly49* gene cluster is under the control of an LCR, and genomic Ly49A transgenes displaying variegated expression argue against an LCR for this locus.[26] Instead, Ly49 expression appears to be a

stochastic event governed by bidirectional promoters upstream of each gene.[27] Another possible silencing mechanism is long-range methylation caused by the repetitive elements in the original targeting construct, now amplified by concatemerization, turning on repeat-dependent DNA methylases whose function is to repress such regions of the genome.[28]

Because 3 related, adjacent gene families (Ly49, CD94/NKG2, KLRI) are silenced in NKC^{KD}, any of the 3, or combinations thereof, may be responsible for the loss of MHC-I immunosurveillance. When both MHC-Ia and β_2m-dependent MHC-Ib molecules are absent, as in the case of β_2m-deficient cells, the rejection by WT NK cells is higher than that seen when only MHC-Ia molecules are absent ($H2K^{b-/-}H2D^{b-/-}$; Figure 3G). This suggests that β_2m-dependent MHC-Ib molecules are also used by NK cells to monitor missing self-MHC expression. Expression of MHC-Ib molecules such as Qa-1^b, H-2^{Blastocyst}, CD1d, and Q9 have all been shown to inhibit NK-cell cytotoxicity.[29-32] However, only one inhibitory receptor for Qa-1^b has been identified (NKG2A).[33] The ligand for KLRI is unknown, but the structural and primary homology to the NKG2 family suggests that KLRI ligands may also be MHC-Ib proteins. In the specific case of target cells from $H2K^{b-/-}H2D^{b-/-}$ and $H2K^{b-/-}$ mice, the defective in vitro and in vivo killing by NKC^{KD} NK cells can be mostly attributed to the loss of Ly49 expression. Ly49 molecules are known to be direct receptors for the K^b and D^b MHC-Ia molecules on NK cells. The absence of D^b by itself did not elicit significant cytotoxicity or rejection (Figures 3E and 4D), in agreement with prior studies showing that K^b is a stronger self-educating ligand than D^b in mice with B6- or 129-derived Ly49 haplotypes.[14,34] Transgenic expression of a Ly49 that can bind to both H-2^b MHC-Ia molecules restored most of the missing self-responses, suggesting that the loss of MHC-I immunosurveillance in NKC^{KD} mice can be attributed mostly to Ly49 down-regulation.

Cytokine production is not strictly dependent on Ly49 expression; high levels of IFN-γ production are clearly evident in Ly49/NKG2-negative cells in NKC^{KD} NK cells after stimulation by tumor cells, activating receptor crosslinking, or pharmacologic stimulation (Figure 7C). However, Ly49/NKG2-negative NK cells in WT mice do not produce significant amounts of IFN-γ after the same stimulation, suggests a possible compensatory mechanism when most NK cells do not express self–MHC-I–specific receptors, such that NK-cell cytokine production is preserved. Most of the IFN-γ produced during MCMV infection originates from "unlicensed" Ly49C/I-negative NK cells.[35] Our findings showing that NK-cell IFN-γ production is normal in NKC^{KD} mice after MCMV infection (Figure 7B) are consistent with this report.

NKC^{KD} NK cells are not entirely hyporesponsive because they kill NKG2D-ligand–positive cells as efficiently as WT NK cells, in agreement with the near normal levels of NKG2D and normal levels of granzyme A and B in NKC^{KD} NK cells. The high killing of YAC-1 and RMA-S-Rae-1β by NKC^{KD} NK cells (as well as $B2m^{-/-}$ NK cells) suggests that the MHC-I requirement for education is less important for the recognition of MHC-I–deficient cells that possess additional activating signals, such as NKG2D ligands, or ligands for Ly49H. Thus, with respect to cytotoxicity NK cells from NKC^{KD} mice are most hyporesponsive toward MHC-I–deficient cells, whereas cytotoxicity triggered through activating receptors is normal. Previous publications have reported that uneducated NK cells have decreased responses when directly stimulated through activating receptors and in response to tumor

cells.[7,36,37] Our contrasting data showing that NKC^{KD} NK cells exhibit normal lysis of these cells suggest that responses to MHC-deficient cells are more sensitive to educating effects than responses to cells bearing activating ligands. However, because MHC-deficient NK cells typically show weaker responses to cells bearing activating ligands, our data may suggest that NKC^{KD} NK cells display a limiting but still minimally active amount of MHC-specific inhibitory receptors. Those receptors could be small amounts of residual Ly49/NKG2 receptors or alternatively could be distinct receptors that compensate for the absence of Ly49/NKG2 receptors.

It has been proposed that MHC-I–uneducated NK cells are less sensitive to stimulatory ligands, but also cannot receive inhibitory signals in response to self–MHC-I molecules.[38] Such a balance of signals is consistent with the normal lysis of RMA cells in ADCC assays (Figure 5A) or of Rae-1ε^{Tg} cells (Figure 3F) by NKC^{KD} NK cells. The use of IL-2–activated NK cells in cytotoxicity assays may explain the discrepancy between our results and previously published studies; IL-2 can render hyporesponsive NK cells functional.[8] By contrast, the almost equal rejection of RMA-S-Rae-1β and $B2m^{-/-}$ Rae-1ε^{tg} cells by NKC^{KD} mice (Figure 6E-F) and the near normal killing of YAC-1 shown by fresh ex vivo NKC^{KD} NK cells (Figure 6G) suggest that strong activation signals override defective missing self-responses in naive NK cells as well. Our findings provide new insight into the contribution of Ly49 molecules to the missing-self and NK-cell education hypotheses. NKC^{KD} mice will be a useful tool for future research into the role of MHC-I recognition by NK cells in various immune settings, including infectious disease, transplant rejection, and neoplasia.

Authorship

Contribution: S.B. designed and performed most experiments and co-wrote the manuscript; M.M.T., M.M.A.R., A.B.M., R.P., L.-H.T., and A.D.T. performed experiments; B.T.W., J.-R.L., and Q.Z. designed and performed experiments; K.S.T. and D.H.R. provided reagents and analyzed results; and A.P.M. designed and performed experiments, supervised research, and wrote the manuscript.

Conflict-of-interest disclosure: D.H.R. is on the Scientific Advisory Board of a biotechnology company, Innate Pharma, that seeks to mobilize NK cells for cancer therapy and receives research funding from a pharmaceutical company, Novo Nordisk, to determine the role of NK cells and NK receptors in inflammatory disease. The remaining authors declare no competing financial interests.

Correspondence: Andrew P. Makrigiannis, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Guindon Hall, Room 4226, 451 Smyth Road, Ottawa, ON, K1H 8M5, Canada; e-mail: amakrigi@uottawa.ca.

References

1. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. *N Engl J Med.* 1989;320(26):1731-1735.

2. Orange JS. Human natural killer cell deficiencies. *Curr Opin Allergy Clin Immunol.* 2006;6(6):399-409.

3. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature.* 1986;319(6055):675-678.

4. Carlyle JR, Mesci A, Fine JH, et al. Evolution of the Ly49 and Nkrp1 recognition systems. *Semin Immunol.* 2008;20(6):321-330.

5. Makrigiannis AP, Patel D, Goulet ML, Dewar K, Anderson SK. Direct sequence comparison of two divergent class I MHC natural killer cell receptor haplotypes. *Genes Immun.* 2005;6(2):71-83.

6. Pyzik M, Charbonneau B, Gendron-Pontbriand EM, et al. Distinct MHC class I-dependent-activating receptors control cytomegalovirus infection in different mouse strains. *J Exp Med.* 2011;208(5):1105-1117.

7. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. *Blood.* 2005;105(11):4416-4423.

8. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. *Nature.* 2005;436(7051):709-713.

9. Brodin P, Lakshmikanth T, Johansson S, Karre K, Hoglund P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. *Blood.* 2009;113(11):2434-2441.

10. Held W, Raulet DH. Ly49A transgenic mice provide evidence for a major histocompatibility complex-dependent education process in natural killer cell development. *J Exp Med.* 1997;185(12):2079-2088.

11. Hanke T, Takizawa H, McMahon CW, et al. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. *Immunity.* 1999;11(1):67-77.

12. Liu J, Morris MA, Nguyen P, et al. Ly49I NK cell receptor transgene inhibition of rejection of H2b mouse bone marrow transplants. *J Immunol.* 2000;164(4):1793-1799.

13. Champsaur M, Beilke JN, Ogasawara K, et al. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1. *J Immunol.* 2010;185(1):157-165.

14. Patel R, Belanger S, Tai LH, Troke AD, Makrigiannis AP. Effect of Ly49 haplotype variance on NK cell function and education. *J Immunol.* 2010;185(8):4783-4792.

15. Belanger S, Tai LH, Anderson SK, Makrigiannis AP. Ly49 cluster sequence analysis in a mouse model of diabetes: an expanded repertoire of activating receptors in the NOD genome. *Genes Immun.* 2008;9(6):509-521.

16. Makrigiannis AP, Pau AT, Schwartzberg PL, et al. A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice. *Genomics.* 2002;79(3):437-444.

17. Carlyle JR, Mesci A, Ljutic B, et al. Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. *J Immunol.* 2006;176(12):7511-7524.

18. Saether PC, Westgaard IH, Flornes LM, et al. Molecular cloning of KLRI1 and KLRI2, a novel pair of lectin-like natural killer-cell receptors with opposing signalling motifs. *Immunogenetics.* 2005;56(11):833-839.

19. Tai LH, Goulet ML, Belanger S, et al. Positive regulation of plasmacytoid dendritic cell function via Ly49Q recognition of class I MHC. *J Exp Med.* 2008;205(13):3187-3199.

20. Corral L, Hanke T, Vance RE, Cado D, Raulet DH. NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. *Eur J Immunol.* 2000;30(3):920-930.

21. Scarpellino L, Oeschger F, Guillaume P, et al. Interactions of Ly49 family receptors with MHC class I ligands in trans and cis. *J Immunol.* 2007;178(3):1277-1284.

22. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. *Nat Immunol.* 2000;1(2):119-126.

23. Piontek GE, Taniguchi K, Ljunggren HG, et al. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. *J Immunol.* 1985;135(6):4281-4288.

24. Orr MT, Beilke JN, Proekt I, Lanier LL. Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus. *Proc Natl Acad Sci U S A.* 2010;107(36):15844-15849.

25. Pham CT, MacIvor DM, Hug BA, Heusel JW, Ley TJ. Long-range disruption of gene expression by a selectable marker cassette. *Proc Natl Acad Sci U S A*. 1996;93(23):13090-13095.

26. Tanamachi DM, Moniot DC, Cado D, et al. Genomic Ly49A transgenes: basis of variegated Ly49A gene expression and identification of a critical regulatory element. *J Immunol*. 2004; 172(2):1074-1082.

27. Saleh A, Davies GE, Pascal V, et al. Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation. *Immunity*. 2004;21(1): 55-66.

28. Smith E, Shilatifard A. The A, B, Gs of silencing. *Genes Dev*. 2007;21(10):1141-1144.

29. Chang CS, Brossay L, Kronenberg M, Kane KP. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. *J Exp Med*. 1999;189(3):483-491.

30. Chiang EY, Henson M, Stroynowski I. The non-classical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. *J Immunol*. 2002;168(5):2200-2211.

31. Salcedo M, Colucci F, Dyson PJ, et al. Role of Qa-1(b)-binding receptors in the specificity of developing NK cells. *Eur J Immunol*. 2000;30(4): 1094-1101.

32. Tajima A, Tanaka T, Ebata T, et al. Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo. *J Immunol*. 2003;171(4):1715-1721.

33. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major his-tocompatibility complex (MHC) class I molecule Qa-1(b). *J Exp Med*. 1998;188(10):1841-1848.

34. Johansson S, Johansson M, Rosmaraki E, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. *J Exp Med*. 2005;201(7):1145-1155.

35. Orr MT, Murphy WJ, Lanier LL. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. *Nat Immunol*. 2010;11(4):321-327.

36. Dorfman JR, Zerrahn J, Coles MC, Raulet DH. The basis for self-tolerance of natural killer cells in beta2-microglobulin and TAP-1 mice. *J Immunol*. 1997;159(11):5219-5225.

37. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. *Science*. 1991;253(5016):199-202.

38. Raulet DH, Vance RE. Self-tolerance of natural killer cells. *Nat Rev Immunol*. 2006;6(7):520-531.